Company Encyclopedia
View More
name
SINOMED
688108.SH
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional devices in China. Its products include coronary drug stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents. The company was founded in 2007 and is headquartered in Tianjin, China.
884.63 B
688108.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking16/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.81%C
    • Profit Margin6.65%B
    • Gross Margin67.00%A
  • Growth ScoreB
    • Revenue YoY20.85%A
    • Net Profit YoY481.06%A
    • Total Assets YoY4.59%C
    • Net Assets YoY3.67%C
  • Cash ScoreB
    • Cash Flow Margin1503.38%B
    • OCF YoY20.85%A
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreB
    • Gearing Ratio30.40%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SinoMed Gets South Korea Approval for Tradent Catheter

    SinoMed Gets South Korea Approval for Tradent Catheter

    marketscreener·
    SH
    688108
    +1.12%
    marketscreener·
    SH
    688108
    +1.12%

    SINOMED: The spiny protrusion balloon product has obtained foreign medical device registration certification

    SINOMED announced that its TRADENT TM coronary balloon dilation catheter has received approval from the Korean MFDS and obtained a medical device registration certificate. This product is suitable for dilating coronary artery stenosis, and the acquisition of the registration certificate will increase the variety of products the company offers overseas, effectively combining with existing coronary stents, coronary balloons, and other products to promote the company's sales abroad

    Zhitong·
    SH
    688108
    +1.12%
    Zhitong·
    SH
    688108
    +1.12%

    The medical consumables sector has undergone significant adjustments, with SINOMED hitting the limit down

    The medical consumables sector has undergone significant adjustments, with SINOMED hitting the limit down, and Tianyi Medical, Double Medical, Guoke Hengtai, ZHYL, Jet Bio-Filtration, and NANFANG MEDICAL also following suit

    Zhitong·
    SZ
    301097
    +2.14%
    SZ
    002901
    0.00%
    SH
    688108
    +1.12%
    Zhitong·
    SZ
    301097
    +2.14%
    SZ
    002901
    0.00%
    SH
    688108
    +1.12%

    SINOMED: The domestic registration of the subsidiary's product COMETIU stent has not been approved

    SINOMED's subsidiary, SINOMED Shenchang Medical Technology Co., Ltd., has not received approval from the National Medical Products Administration for the COMETIU stent registration application. The product applied for EU MDR certification from DEKRA Certification B.V. in 2024 and has passed the on-site audit, currently in the technical review stage. At the same time, the COMETIU stent received breakthrough medical device designation from the US FDA in 2025, becoming the world's first product for the treatment of intracranial atherosclerotic stenosis

    Zhitong·
    SH
    688108
    +1.12%
    Zhitong·
    SH
    688108
    +1.12%

    SINOMED: Sun Jianhua's holdings decreased to 19.3156%

    SINOMED announced that the actual controller Sun Jianhua signed the "Agreement on Termination of Joint Action" with Yangguang Deye, Yangguang Guangye, Yangguang Yongye, and Yangguang Fuye on October 17, 2025. After the termination of the joint action relationship, his controlled company's shares decreased from 101 million shares, accounting for 24.3641%, to 80.3704 million shares, accounting for 19.3156%. The number of shares held directly and indirectly by the information disclosure obligor remains unchanged. This equity change does not involve an increase or decrease in shares, a tender offer, nor does it lead to a change in the company's controlling shareholder or actual controller

    Zhitong·
    SH
    688108
    +1.12%
    Zhitong·
    SH
    688108
    +1.12%
    © 2025 Longbridge｜Disclaimer